Chembio Diagnostics (CEMI) 7.35 $CEMI
Chembio Diagnostics, Inc. Announces Upsizing And Pricing Of Public Offering Of Common Stock
GlobeNewswire - Fri Jul 29, 5:12AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases ("Chembio" or the "Company"
, today announced the upsizing and pricing of its previously announced underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $6.00 per share. In addition, Chembio has granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any. All shares of common stock to be sold in the offering will be offered by Chembio. The offering is expected to close on or about August 3, 2016, subject to the satisfaction of customary closing conditions.
CEMI: 7.35 (+0.42)
Chembio's DPP(R) Zika IgM/IgG Assay Obtains CE Mark for Rapid Point-of-Care Detection of Zika Virus
GlobeNewswire - Wed Jul 27, 5:55AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has obtained a CE mark for its DPP Zika IgM/IgG Assay. The Chembio DPP Zika IgM/IgG System, which includes an assay utilizing the patented DPP technology, as well as a digital reader, the DPP Micro Reader, are now cleared for commercialization and for sale in 17 European countries, including the United Kingdom, Germany, and France, as well as a majority of the Caribbean nations, not including Puerto Rico.
CEMI: 7.35 (+0.42)
Chembio Diagnostics Announces Proposed Public Offering of Common Shares
GlobeNewswire - Mon Jul 25, 7:34AM CDT
Chembio Diagnostics, Inc. (NASDAQ:CEMI) (the "Company" today announced that it has commenced an underwritten public offering of $10.0 million of common shares (the "Offering" . In addition, the Company intends to grant the underwriters a 30-day option to purchase additional shares equal to up to 15% of the aggregate number of shares to be sold in the Offering to cover over-allotments, if any.
CEMI: 7.35 (+0.42)
Chembio Diagnostics Announces Preliminary Second Quarter 2016 Results
GlobeNewswire - Mon Jul 25, 6:45AM CDT
Chembio Diagnostics, Inc. (NASDAQ:CEMI) (the "Company" today announced preliminary financial results for the second quarter of 2016. The following amounts discussed are unaudited and preliminary and are subject to the Company's management and independent auditor completing their customary closing and review procedures following the quarter, among other factors. For the three months ended June 30, 2016, the Company expects to report total revenue in the range of $3.20 to $3.30 million, and an operating loss in the range of $2.30 to $2.50 million. In addition, for the three months ended June 30, 2016, the Company plans to charge a $6.0 million valuation allowance on its deferred tax asset, as the Company believes that it is more likely than not that the deferred tax asset will not be realized in the foreseeable future based on information available at this time. This conclusion was reached primarily because of longer than expected delays in regulatory approvals for our Zika assays, which was not known at the time of determining the amount of the deferred tax asset as of December 31, 2015, and has resulted in uncertainties related to future taxable income, in terms of both its timing and its sufficiency in order to maintain the deferred tax asset. Including this non-cash expense for the valuation allowance, the Company estimates that its net loss for the three months ended June 30, 2016 will be in the range $8.30 million to $8.50 million.
CEMI: 7.35 (+0.42)
The Top 200 Point-Of-Care Diagnostics Companies Worldwide
PR Newswire - Wed Jun 22, 3:33PM CDT
Did you know?
CEMI: 7.35 (+0.42)
Chembio Launches U.S. Sales of its SURE CHECK(R) HIV 1/2 Assay and Reduces Prices of HIV Tests for U.S. Public Health Market
GlobeNewswire - Wed Jun 01, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced the launch of U.S. sales of its Chembio-branded SURE CHECKHIV 1/2 Assay. In connection with this launch, the Company is implementing a new pricing strategy for its POC HIV products for the U.S. public health market with the goal of increasing testing frequency and reducing rates of HIV infection. Effective immediately, the Company will begin selling its HIV tests in the U.S. public health market at a price of five dollars ($5.00) per test, which represents a significant discount from current pricing.
CEMI: 7.35 (+0.42)
Chembio Diagnostics Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 12, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC" diagnostic tests for infectious diseases, today reported financial results for the three months ended March 31, 2016.
CEMI: 7.35 (+0.42)
Investor Calendar Invites You to the Chembio First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016
ACCESSWIRE - Wed May 11, 3:10PM CDT
MEDFORD, NY / ACCESSWIRE / May 11, 2016 / Chembio Diagnostics, Inc. (NASDAQ: CEMI) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 12, 2016 at 10:00 AM Eastern Time.
CEMI: 7.35 (+0.42)
Chembio and Bio-Manguinhos Announce Plans to Introduce a Point-of-Care Diagnostic Test for Zika Virus in Brazil
GlobeNewswire - Thu May 05, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced the status of its plans with Bio-Manguinhos/Fiocruz to obtain regulatory approval and to introduce a POC diagnostic test for Zika virus in Brazil. The announcement coincides with the 40th anniversary of Bio-Manguinhos, which was recognized at the Third International Symposium of Immunobiologicals, held May 2-5, 2016 in Rio de Janeiro, Brazil.
CEMI: 7.35 (+0.42)
Chembio to Host Conference Call to Discuss First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 7:50AM CDT
Chembio Diagnostics, Inc. (NASDAQ:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the first quarter of 2016, before the opening of the market on Thursday, May 12, 2016. The Company's 10-Q and earnings press release will be available at 9:15 a.m. on our web site.
CEMI: 7.35 (+0.42)
Chembio Awarded Grant to Develop First Oral Fluid/Saliva Point-of-Care Diagnostic Test for Malaria
GlobeNewswire - Mon Apr 25, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has been awarded a $678,000 grant from the Bill & Melinda Gates Foundation to expedite the feasibility testing and development of the world's first oral fluid/saliva POC diagnostic test to simply and accurately identify individuals infected with all species of malaria.
CEMI: 7.35 (+0.42)
Chembio Diagnostics Reports 2015 Financial Results
GlobeNewswire - Tue Mar 08, 8:44AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC" diagnostic tests for infectious diseases, today reported financial results for the year ended December 31, 2015.
CEMI: 7.35 (+0.42)
Investor Calendar Invites You to the Chembio Diagnostics Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Tuesday, March 8, 2016
ACCESSWIRE - Mon Mar 07, 3:08PM CST
MEDFORD, NY / ACCESSWIRE / March 7, 2016 / Chembio Diagnostics, Inc. (NASDAQ: CEMI) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held Tuesday, March 8, 2016 at 10:00 AM Eastern Time.
CEMI: 7.35 (+0.42)
Chembio to Collaborate With Bio-Manguinhos/Fiocruz to Develop Point-of-Care Zika Diagnostic Tests for Brazil
GlobeNewswire - Mon Mar 07, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced plans to collaborate with Bio-Manguinhos/Fiocruz for the development of POC Zika diagnostic tests for Brazil.
CEMI: 7.35 (+0.42)
Chembio to sell SURE CHECK HIV 1/2 Assay in the US via existing US sales force & distribution channels
M2 - Wed Jan 27, 3:06AM CST
Diagnostic company Chembio Diagnostics (NasdaqCM:CEMI) stated on Tuesday that it will start selling its SURE CHECK HIV 1/2 Assay in the US market with effect from 1 June 2016.
CEMI: 7.35 (+0.42)
Chembio to Sell Its SURE CHECK(R) HIV 1/2 Assay in the United States Beginning June 1, 2016
GlobeNewswire - Tue Jan 26, 11:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, will begin selling its SURE CHECK(R) HIV 1/2 Assay in the U.S. market on June 1, 2016. The product is currently distributed in the U.S. by Alere, Inc. under Alere's Clearview(R) COMPLETE brand ("Alere" , and Chembio has notified Alere that Chembio will not renew or extend the U.S. SURE CHECK(R) HIV 1/2 Assay distribution agreement when the agreement terminates, effective May 31, 2016.
CEMI: 7.35 (+0.42)
3 Stocks Tackling Concussion Issues in Pro Athletes
ACCESSWIRE - Wed Jan 20, 7:45AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 20, 2016 / The 2015 drama Concussion starring Will Smith follows the story of Dr. Bennet Omalu's battle with the National Football League to acknowledge research on the brain damage suffered by professional football players. After examining the brains of many deceased NFL players, Dr. Omalu coined the term chronic traumatic encephalopathy (CTE) to represent the large accumulation of tau protein on the brain causing a wide range of mental problems.
STEM: 0.38 (+0.01), CEMI: 7.35 (+0.42), CUR: 0.23 (-0.01)
The Top 100 Manufacturers Of Point-Of-Care Instruments & Tests
PR Newswire - Thu Dec 31, 9:20AM CST
Did you know?
CEMI: 7.35 (+0.42)
The World Market for Infectious Disease Diagnostic Tests 2015
M2 - Tue Dec 08, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/xqr64g/the_world_market) has announced the addition of the "The World Market for Infectious Disease Diagnostic Tests 2015" report to their offering. Infectious disease tests are one of the most dynamic spaces in the in vitro diagnostics (IVD) industry. Companies in the market need to stay aware of competitive trends and medical trends as occasional explosive market growth in the infectious disease test market can occur with the emergence of new disease threats or acceptance of new routine screening procedures. This report contains detailed market estimates and forecasts for four major areas of infectious disease testing, including identification and antibiotic susceptibility testing, immunoassays, molecular testing and blood screening. POC and home testing markets for infectious disease are also provided. Infectious diseases are also the frequent target of novel technology applications including PCR-alternative molecular amplification methods, next-generation sequencing (NGS), microarrays, and mass spectrometry. Advancements in instrument automated analysis and microfluidics have allowed for the proliferation of infectious disease testing across settings and institutions - from traditional sites such as reference labs through physician office laboratories (POLs) and mobile clinics in the developing world. Sales and forecasts of infectious disease reagents are made through to 2020. Emerging products and markets are described; key players and strategies discussed and competitive trends are analyzed. In addition to providing useful market data for business planning efforts, the report covers important trends in the industry. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction to Infectious Diseases in Healthcare Chapter Three: Trends in Clinical Infectious Diseases Capter Four: Overview of the Infectious Disease Test Market Chapter Five: The Market for Microbiology Id/Ast Testing Chapter Six: The Market for Immunoassays Chapter Seven: The Market for Molecular Assays Chapter Eight: The Infectious Disease Blood Screening Market Chapter Nine: Company Profiles - Alere - Beckman Coulter - Becton, Dickinson & Co. (BD) - bioM?rieux - Bio-Rad Laboratories - Cepheid - Chembio Diagnostics Systems - DiaSorin - Grifols - Hologic - Meridian Bioscience - OraSure Technologies - Ortho-Clinical Diagnostics - Qiagen - Quidel Corporation - Roche Diagnostics - Siemens Healthcare Diagnostics - Thermo Fisher Scientific - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/xq...rld_market
BDX: 176.79 (+0.79), VIVO: 19.58 (+0.22), CPHD: 36.91 (+1.58), TRIB: 12.98 (+0.15), HOLX: 39.00 (+0.51), CEMI: 7.35 (+0.42), OSUR: 6.80 (-0.02)
Chembio Diagnostics, Inc. Announces Upsizing And Pricing Of Public Offering Of Common Stock
GlobeNewswire - Fri Jul 29, 5:12AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases ("Chembio" or the "Company"
, today announced the upsizing and pricing of its previously announced underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $6.00 per share. In addition, Chembio has granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock to cover over-allotments, if any. All shares of common stock to be sold in the offering will be offered by Chembio. The offering is expected to close on or about August 3, 2016, subject to the satisfaction of customary closing conditions. CEMI: 7.35 (+0.42)
Chembio's DPP(R) Zika IgM/IgG Assay Obtains CE Mark for Rapid Point-of-Care Detection of Zika Virus
GlobeNewswire - Wed Jul 27, 5:55AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has obtained a CE mark for its DPP Zika IgM/IgG Assay. The Chembio DPP Zika IgM/IgG System, which includes an assay utilizing the patented DPP technology, as well as a digital reader, the DPP Micro Reader, are now cleared for commercialization and for sale in 17 European countries, including the United Kingdom, Germany, and France, as well as a majority of the Caribbean nations, not including Puerto Rico.
CEMI: 7.35 (+0.42)
Chembio Diagnostics Announces Proposed Public Offering of Common Shares
GlobeNewswire - Mon Jul 25, 7:34AM CDT
Chembio Diagnostics, Inc. (NASDAQ:CEMI) (the "Company"
today announced that it has commenced an underwritten public offering of $10.0 million of common shares (the "Offering" . In addition, the Company intends to grant the underwriters a 30-day option to purchase additional shares equal to up to 15% of the aggregate number of shares to be sold in the Offering to cover over-allotments, if any. CEMI: 7.35 (+0.42)
Chembio Diagnostics Announces Preliminary Second Quarter 2016 Results
GlobeNewswire - Mon Jul 25, 6:45AM CDT
Chembio Diagnostics, Inc. (NASDAQ:CEMI) (the "Company"
today announced preliminary financial results for the second quarter of 2016. The following amounts discussed are unaudited and preliminary and are subject to the Company's management and independent auditor completing their customary closing and review procedures following the quarter, among other factors. For the three months ended June 30, 2016, the Company expects to report total revenue in the range of $3.20 to $3.30 million, and an operating loss in the range of $2.30 to $2.50 million. In addition, for the three months ended June 30, 2016, the Company plans to charge a $6.0 million valuation allowance on its deferred tax asset, as the Company believes that it is more likely than not that the deferred tax asset will not be realized in the foreseeable future based on information available at this time. This conclusion was reached primarily because of longer than expected delays in regulatory approvals for our Zika assays, which was not known at the time of determining the amount of the deferred tax asset as of December 31, 2015, and has resulted in uncertainties related to future taxable income, in terms of both its timing and its sufficiency in order to maintain the deferred tax asset. Including this non-cash expense for the valuation allowance, the Company estimates that its net loss for the three months ended June 30, 2016 will be in the range $8.30 million to $8.50 million. CEMI: 7.35 (+0.42)
The Top 200 Point-Of-Care Diagnostics Companies Worldwide
PR Newswire - Wed Jun 22, 3:33PM CDT
Did you know?
CEMI: 7.35 (+0.42)
Chembio Launches U.S. Sales of its SURE CHECK(R) HIV 1/2 Assay and Reduces Prices of HIV Tests for U.S. Public Health Market
GlobeNewswire - Wed Jun 01, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced the launch of U.S. sales of its Chembio-branded SURE CHECKHIV 1/2 Assay. In connection with this launch, the Company is implementing a new pricing strategy for its POC HIV products for the U.S. public health market with the goal of increasing testing frequency and reducing rates of HIV infection. Effective immediately, the Company will begin selling its HIV tests in the U.S. public health market at a price of five dollars ($5.00) per test, which represents a significant discount from current pricing.
CEMI: 7.35 (+0.42)
Chembio Diagnostics Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 12, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, today reported financial results for the three months ended March 31, 2016. CEMI: 7.35 (+0.42)
Investor Calendar Invites You to the Chembio First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016
ACCESSWIRE - Wed May 11, 3:10PM CDT
MEDFORD, NY / ACCESSWIRE / May 11, 2016 / Chembio Diagnostics, Inc. (NASDAQ: CEMI) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 12, 2016 at 10:00 AM Eastern Time.
CEMI: 7.35 (+0.42)
Chembio and Bio-Manguinhos Announce Plans to Introduce a Point-of-Care Diagnostic Test for Zika Virus in Brazil
GlobeNewswire - Thu May 05, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced the status of its plans with Bio-Manguinhos/Fiocruz to obtain regulatory approval and to introduce a POC diagnostic test for Zika virus in Brazil. The announcement coincides with the 40th anniversary of Bio-Manguinhos, which was recognized at the Third International Symposium of Immunobiologicals, held May 2-5, 2016 in Rio de Janeiro, Brazil.
CEMI: 7.35 (+0.42)
Chembio to Host Conference Call to Discuss First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 7:50AM CDT
Chembio Diagnostics, Inc. (NASDAQ:CEMI), which develops, manufactures, markets and licenses point-of-care diagnostic tests, announced today that the Company will release financial results for the first quarter of 2016, before the opening of the market on Thursday, May 12, 2016. The Company's 10-Q and earnings press release will be available at 9:15 a.m. on our web site.
CEMI: 7.35 (+0.42)
Chembio Awarded Grant to Develop First Oral Fluid/Saliva Point-of-Care Diagnostic Test for Malaria
GlobeNewswire - Mon Apr 25, 7:50AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has been awarded a $678,000 grant from the Bill & Melinda Gates Foundation to expedite the feasibility testing and development of the world's first oral fluid/saliva POC diagnostic test to simply and accurately identify individuals infected with all species of malaria.
CEMI: 7.35 (+0.42)
Chembio Diagnostics Reports 2015 Financial Results
GlobeNewswire - Tue Mar 08, 8:44AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, today reported financial results for the year ended December 31, 2015. CEMI: 7.35 (+0.42)
Investor Calendar Invites You to the Chembio Diagnostics Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Tuesday, March 8, 2016
ACCESSWIRE - Mon Mar 07, 3:08PM CST
MEDFORD, NY / ACCESSWIRE / March 7, 2016 / Chembio Diagnostics, Inc. (NASDAQ: CEMI) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2015, to be held Tuesday, March 8, 2016 at 10:00 AM Eastern Time.
CEMI: 7.35 (+0.42)
Chembio to Collaborate With Bio-Manguinhos/Fiocruz to Develop Point-of-Care Zika Diagnostic Tests for Brazil
GlobeNewswire - Mon Mar 07, 7:50AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced plans to collaborate with Bio-Manguinhos/Fiocruz for the development of POC Zika diagnostic tests for Brazil.
CEMI: 7.35 (+0.42)
Chembio to sell SURE CHECK HIV 1/2 Assay in the US via existing US sales force & distribution channels
M2 - Wed Jan 27, 3:06AM CST
Diagnostic company Chembio Diagnostics (NasdaqCM:CEMI) stated on Tuesday that it will start selling its SURE CHECK HIV 1/2 Assay in the US market with effect from 1 June 2016.
CEMI: 7.35 (+0.42)
Chembio to Sell Its SURE CHECK(R) HIV 1/2 Assay in the United States Beginning June 1, 2016
GlobeNewswire - Tue Jan 26, 11:03AM CST
Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, will begin selling its SURE CHECK(R) HIV 1/2 Assay in the U.S. market on June 1, 2016. The product is currently distributed in the U.S. by Alere, Inc. under Alere's Clearview(R) COMPLETE brand ("Alere"
, and Chembio has notified Alere that Chembio will not renew or extend the U.S. SURE CHECK(R) HIV 1/2 Assay distribution agreement when the agreement terminates, effective May 31, 2016. CEMI: 7.35 (+0.42)
3 Stocks Tackling Concussion Issues in Pro Athletes
ACCESSWIRE - Wed Jan 20, 7:45AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 20, 2016 / The 2015 drama Concussion starring Will Smith follows the story of Dr. Bennet Omalu's battle with the National Football League to acknowledge research on the brain damage suffered by professional football players. After examining the brains of many deceased NFL players, Dr. Omalu coined the term chronic traumatic encephalopathy (CTE) to represent the large accumulation of tau protein on the brain causing a wide range of mental problems.
STEM: 0.38 (+0.01), CEMI: 7.35 (+0.42), CUR: 0.23 (-0.01)
The Top 100 Manufacturers Of Point-Of-Care Instruments & Tests
PR Newswire - Thu Dec 31, 9:20AM CST
Did you know?
CEMI: 7.35 (+0.42)
The World Market for Infectious Disease Diagnostic Tests 2015
M2 - Tue Dec 08, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/xqr64g/the_world_market) has announced the addition of the "The World Market for Infectious Disease Diagnostic Tests 2015" report to their offering. Infectious disease tests are one of the most dynamic spaces in the in vitro diagnostics (IVD) industry. Companies in the market need to stay aware of competitive trends and medical trends as occasional explosive market growth in the infectious disease test market can occur with the emergence of new disease threats or acceptance of new routine screening procedures. This report contains detailed market estimates and forecasts for four major areas of infectious disease testing, including identification and antibiotic susceptibility testing, immunoassays, molecular testing and blood screening. POC and home testing markets for infectious disease are also provided. Infectious diseases are also the frequent target of novel technology applications including PCR-alternative molecular amplification methods, next-generation sequencing (NGS), microarrays, and mass spectrometry. Advancements in instrument automated analysis and microfluidics have allowed for the proliferation of infectious disease testing across settings and institutions - from traditional sites such as reference labs through physician office laboratories (POLs) and mobile clinics in the developing world. Sales and forecasts of infectious disease reagents are made through to 2020. Emerging products and markets are described; key players and strategies discussed and competitive trends are analyzed. In addition to providing useful market data for business planning efforts, the report covers important trends in the industry. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction to Infectious Diseases in Healthcare Chapter Three: Trends in Clinical Infectious Diseases Capter Four: Overview of the Infectious Disease Test Market Chapter Five: The Market for Microbiology Id/Ast Testing Chapter Six: The Market for Immunoassays Chapter Seven: The Market for Molecular Assays Chapter Eight: The Infectious Disease Blood Screening Market Chapter Nine: Company Profiles - Alere - Beckman Coulter - Becton, Dickinson & Co. (BD) - bioM?rieux - Bio-Rad Laboratories - Cepheid - Chembio Diagnostics Systems - DiaSorin - Grifols - Hologic - Meridian Bioscience - OraSure Technologies - Ortho-Clinical Diagnostics - Qiagen - Quidel Corporation - Roche Diagnostics - Siemens Healthcare Diagnostics - Thermo Fisher Scientific - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/xq...rld_market
BDX: 176.79 (+0.79), VIVO: 19.58 (+0.22), CPHD: 36.91 (+1.58), TRIB: 12.98 (+0.15), HOLX: 39.00 (+0.51), CEMI: 7.35 (+0.42), OSUR: 6.80 (-0.02)
